比利时艾尔贝姆Ion Beam Applications  www.iba-worldwide.com
IBA在癌症诊断与治疗领域中提供具有独特精确度的解决方案。公司还提供消毒与电离方案以改善日常生活的卫生与安全性。 对抗癌症：肿瘤学连续体 | 
诊断 | 

IBA在粒子回旋加速器的设计以及放射性药物示踪剂的生产和分销领域拥有独特的专业技能。这些示踪剂每天都在医院中大量应用，用来快速精确地探测癌、神经和心脏疾病。
IBA还提供剂量测定产品，在大量医院中用于质量保证，在X射线诊断中用于患者剂量监控。 
癌症治疗 | 

IBA开发了放射性治疗方案和剂量测定设备，用来以最大的精确度来治疗癌症。
IBA是粒子治疗领域内的毫无争议的领袖，被认为是选择性癌细胞破坏领域内最精确和最有效的临床放射性治疗方法。 
消毒 & 电离 | 

IBA正在设计电子加速器和高能X射线，在大量行业中用于消毒医疗设备，对食品产品进行高温消毒，改善聚合物属性。
200多台IBA工业加速器被用于全球达几十年之久。 

 
1947年：Louvain-la-neuve 天主教大学（UCL）的粒子回旋加速器研究中心生产了第一台粒子回旋加速器。
1986年：基于UCL的粒子回旋加速器研究中心，IBA公司正式成立，公司的注册办公地点位于比利时的Louvain-la-Neuve。公司将目标定位于利用在粒子加速器技术领域的专业技能来满足在医药和工业领域中不断增长的需求。
IBA最初从事医学图象处理，后来很快意识到了多元化的必要。因此，公司将注意力转移到放射性治疗，并开发了在治疗各种癌症时具有前所未有的精确度和效率的粒子回旋加速器。
1992年：IBA将业务拓展到消毒和电离等工业领域，向市场推出了Rhodotron。这是一种基于“法国核能委员会”提出的专利概念的粒子加速器。
1998年6月：IBA在Brussels证券市场上市并融资，这使得IBA能够通过内部增长和对其他公司的收购加速发展，所收购的公司的技术和服务加强或补充了IBA的核心竞争力。
IBA began its existence in 1986 as a spin-off of the Cyclotron Research Center of the Catholic University of Louvain-la-Neuve (UCL), which produced its first cyclotron in 1947.
The objective was to exploit a unique expertise in particle accelerator technology to meet growing needs in the fields of medicine and industry.
While initially active in medical imaging, IBA quickly recognized the need to diversify. So, the company turned its attention to radiotherapy and developed cyclotrons able to treat numerous forms of cancer with a degree of precision and efficacy not possible before. Then, in 1992, IBA expanded activities into the industrial sector of Sterilization & Ionization by introducing the Rhodotron®, a new type of particle accelerator based on a patented concept of the French Atomic Energy Commission.

Funds raised on the Brussels stock market from an initial public offering in June 1998 enabled IBA to accelerate progress by internal growth and the acquisition of other companies, all offering technologies and services reinforcing or complementing IBA’s core competencies
IBA develops and markets leading edge technologies, pharmaceuticals and tailor-made solutions for
healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is
also active in the field of industrial sterilization and ionization. Listed on the pan-European stock
exchange EURONEXT, IBA is included in the BelMid Index.
(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).